- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06311578
A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
March 26, 2024 updated by: Johnson & Johnson Enterprise Innovation Inc.
Phase 1 Study of Intratumoral Administration of JNJ-87704916, an Oncolytic Virus, as Monotherapy and in Combination for Advanced Solid Tumors
The purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
66
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Study Contact
- Phone Number: 844-434-4210
- Email: Participate-In-This-Study@its.jnj.com
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- MD Anderson Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- For Part 1: Individuals with a diagnosis of advanced or metastatic solid tumor exhausting all available standard of care therapy
- Have at least 1 injectable tumor
- Eastern cooperative oncology group (ECOG) performance status of grade 0 or 1
- A participant who can have children must have a negative pregnancy test before the first dose of study treatment and during the study
Exclusion Criteria:
- Active disease involvement of the CNS (example, primary central nervous system tumors, metastases, leptomeningeal disease). Some exceptions are allowed
- Prior history of, or active, significant herpetic infections (example, herpetic keratitis or encephalitis) or active herpetic infections that require ongoing systemic anti-viral therapy
- Active infection or condition that requires treatment with systemic anti-infective agents (example, antibiotics, antifungals, or antivirals) within 7 days prior to the first dose of study treatment or chronic use of anti-infective agents
- History of solid organ or hematologic stem cell transplantation
- Known positive test result for human immunodeficiency virus (HIV) or other immunodeficiency syndrome
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part 1: Dose Escalation
Participants with advanced solid tumors will receive JNJ-87704916 alone and in combination with cetrelimab.
Ascending dose levels will be sequentially tested.
|
Cetrelimab will be administered.
Other Names:
JNJ-87704916 will be administered as an intratumoral injection.
|
Experimental: Part 2 Cohort A: Dose Expansion
Participants with relapsed/refractory metastatic non-small cell lung cancer (NSCLC) will receive JNJ-87704916 in combination with cetrelimab at the dose identified in Part 1.
Additional cohorts may be added to evaluate additional disease indications, or treatment regimens.
|
Cetrelimab will be administered.
Other Names:
JNJ-87704916 will be administered as an intratumoral injection.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1: Number of Participants with Dose-Limiting Toxicity (DLT)
Time Frame: Up to 5 years
|
The DLTs are specific adverse events and are defined as any of the following: non-hematological toxicity and hematologic toxicity.
|
Up to 5 years
|
Number of Participants with Adverse Events (AEs) by Severity
Time Frame: From first dose up to 100 days after last dose of study treatment (up to 5 years)
|
An adverse event is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product.
An adverse event does not necessarily have a causal relationship with the treatment.
Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0.
Severity scale ranges from Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life-threatening, and Grade 5: death related to adverse event.
|
From first dose up to 100 days after last dose of study treatment (up to 5 years)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Parts 1 and 2: Percentage of Participants With Objective Response (OR)
Time Frame: Up to 5 years
|
OR is defined as the percentage of participants who have best response of Complete Response (CR) or Partial Response (PR) according to response evaluation criteria in solid tumors (RECIST) v1.1.
|
Up to 5 years
|
Parts 1 and 2: Percentage of Participants With Disease Control (DC)
Time Frame: Up to 5 years
|
DC is defined as the percentage of participants who have achieved complete response, partial response, and stable disease according to RECIST v1.1.
|
Up to 5 years
|
Parts 1 and 2: Duration of Response (DOR)
Time Frame: Up to 5 years
|
DOR will be calculated among responders from the date of initial documentation of a response to the date of first documented evidence of relapse according to RECIST v1.1, or death due to any cause, whichever occurs first.
|
Up to 5 years
|
Part 2: Progression Free Survival (PFS)
Time Frame: From treatment initiation until disease progression or worsening or death due to any cause (up to 5 years)
|
PFS is defined as the time from treatment initiation until disease progression or worsening or death due to any cause.
|
From treatment initiation until disease progression or worsening or death due to any cause (up to 5 years)
|
Part 2: Overall Survival (OS)
Time Frame: From treatment initiation until death due to any cause (up to 5 years)
|
OS is defined as the time from treatment initiation until death due to any cause.
|
From treatment initiation until death due to any cause (up to 5 years)
|
Parts 1 and 2: Number of JNJ-87704916 Genome Copies per Milliliter
Time Frame: Up to 5 years
|
Viral genome copies of JNJ-87704916 collected from samples (that is, blood, urine, oral mucosa, injection sites, and dressings) will be determined by quantitative polymerase chain reaction (qPCR) assays.
|
Up to 5 years
|
Parts 1 and 2: Payload Concentrations of JNJ-87704916
Time Frame: Up to 2 years
|
Blood samples will be collected to characterize JNJ-87704916 payload concentrations in blood and tumor and will be analyzed using immunoassay.
|
Up to 2 years
|
Parts 1 and 2: Number of Participants with JNJ-87704916 Antibodies
Time Frame: Up to 2 years
|
Antibodies against JNJ-87704916 encoded payloads and against herpes simplex virus type-1 (HSV-1) will be analyzed.
|
Up to 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Johnson & Johnson Enterprise Innovation Inc Clinical Trial, Johnson & Johnson Enterprise Innovation Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
March 25, 2024
Primary Completion (Estimated)
November 8, 2028
Study Completion (Estimated)
November 30, 2033
Study Registration Dates
First Submitted
March 8, 2024
First Submitted That Met QC Criteria
March 8, 2024
First Posted (Actual)
March 15, 2024
Study Record Updates
Last Update Posted (Actual)
March 28, 2024
Last Update Submitted That Met QC Criteria
March 26, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 87704916LUC1001
- 2023-506495-27-00 (Registry Identifier: EUCT number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumors
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Solid Tumors, Neoplasms, Advanced SolidHungary
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Alphamab (Australia) Co Pty Ltd.RecruitingAdvanced Solid Tumors | Metastatic Solid TumorsAustralia
-
Jiangsu Simcere Pharmaceutical Co., Ltd.UnknownAdvanced Solid Tumors | Metastatic Solid TumorsChina
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
Clinical Trials on Cetrelimab
-
Johnson & Johnson Enterprise Innovation Inc.RecruitingCarcinoma, Non-small-Cell LungKorea, Republic of, Spain, United States, Germany
-
Janssen Research & Development, LLCCompletedHepatitis B, ChronicFrance, Germany, Spain, Poland, Belgium
-
Janssen Research & Development, LLCRecruitingUrinary Bladder NeoplasmsUnited States, Korea, Republic of, France, Israel, Spain, Italy, United Kingdom, Belgium, Germany, Netherlands
-
Janssen Research & Development, LLCActive, not recruitingNeoplasmsUnited Kingdom, Spain, United States, Russian Federation, Poland, Sweden, Moldova, Republic of
-
Janssen Pharmaceutical K.K.Completed
-
Janssen Research & Development, LLCActive, not recruitingUrothelial CarcinomaFrance, United States, Korea, Republic of, Belgium, Poland, Taiwan, Turkey, Russian Federation, Spain, Italy, United Kingdom, Brazil, Belarus
-
Rahul AggarwalJanssen Scientific Affairs, LLCActive, not recruitingProstate Cancer | Small Cell Carcinoma | Small Cell Neuroendocrine CarcinomaUnited States
-
Janssen Research & Development, LLCRecruitingCarcinoma, Non-Small-Cell LungKorea, Republic of, United States, Malaysia, Turkey
-
Janssen Research & Development, LLCRecruitingMetastatic Castration-resistant Prostate NeoplasmsUnited States, Australia
-
Janssen Research & Development, LLCRecruitingBladder CancerUnited States, Belgium, Korea, Republic of, Italy, Taiwan, China, United Kingdom, Germany, France, Argentina, Brazil, Poland, Spain, Czechia, Japan, Netherlands, India, Canada, Mexico, Australia, Portugal